carbenoxolone sodium has been researched along with Obesity in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Islam, SA; Moon, SS; Seo, M | 1 |
| Chen, Y; Qian, Q; Yu, J | 1 |
| Campello, RS; Machado, UF; Mori, RC; Poças da Silva, T | 1 |
| Chen, Y; Jin, Z; Lu, W; Shi, B; Yu, J | 1 |
| Iwamura, T; Kainoh, M; Kawai, K; Kumagai, H; Nakaki, J; Nitta, A; Okazaki, S; Sakami, S; Sato, M; Sekiya, Y; Takahashi, T; Yagi, M | 1 |
| Du, H; Friedman, TC; Liu, L; Liu, Y; Lutfy, K; Nakagawa, Y; Ren, X; Wang, W; Wang, Y | 1 |
| Fotsch, C; Wang, M | 1 |
| Gathercole, LL; Stewart, PM | 1 |
| Dhanesha, N; Dhote, V; Jain, M; Joharapurkar, A; Kshirsagar, S; Shah, G; Sharma, A | 1 |
| Acharya, V; Ayyalasomayajula, V; Koppala, SR; Nemani, H; Ponday, LR; Pothana, S; Prasad Sakamuri, SS; Prathipati, VK; Putcha, UK; Sukapaka, M; Veetill, GN | 1 |
| Livingstone, DE; Walker, BR | 1 |
| Andrew, R; Andrews, RC; Homer, NZ; Sandeep, TC; Smith, K; Walker, BR | 1 |
| Abdallah, BM; Beck-Nielsen, H; Gaster, M | 1 |
| Hachey, DL; Hasty, AH; Nuotio-Antar, AM | 1 |
| Stimson, RH; Walker, BR | 1 |
| Flatt, PR; Gault, VA; Irwin, N; McKillop, AM; Taylor, A | 1 |
2 review(s) available for carbenoxolone sodium and Obesity
| Article | Year |
|---|---|
Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Carbenoxolone; Diabetes Mellitus; Enzyme Inhibitors; Humans; Hydrocortisone; Obesity | 2010 |
Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Adult; Animals; Carbenoxolone; Cushing Syndrome; Diet; Glucocorticoids; Humans; Hyperandrogenism; Hypothalamo-Hypophyseal System; Liver; Male; Metabolic Syndrome; Mice; Mice, Knockout; Mice, Transgenic; Obesity; Organ Specificity; Pituitary-Adrenal System; Rats | 2007 |
1 trial(s) available for carbenoxolone sodium and Obesity
| Article | Year |
|---|---|
Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Adult; Carbenoxolone; Cortisone; Cross-Over Studies; Double-Blind Method; Humans; Hydrocortisone; Insulin; Male; Middle Aged; Obesity | 2005 |
13 other study(ies) available for carbenoxolone sodium and Obesity
| Article | Year |
|---|---|
Acute anti-obesity effects of intracerebroventricular 11β-HSD1 inhibitor administration in diet-induced obese mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Anti-Obesity Agents; Body Weight; Carbenoxolone; Diet, High-Fat; Eating; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Hypothalamus; Injections, Intraventricular; Insulin; Leptin; Male; Mechanistic Target of Rapamycin Complex 1; Membrane Glycoproteins; Mice; Neurons; Obesity; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; X-Box Binding Protein 1 | 2018 |
Carbenoxolone ameliorates insulin sensitivity in obese mice induced by high fat diet via regulating the IκB-α/NF-κB pathway and NLRP3 inflammasome.
Topics: Animals; Carbenoxolone; Diet, High-Fat; Gene Expression Regulation; Inflammation; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; NF-kappa B; NF-KappaB Inhibitor alpha; NLR Family, Pyrin Domain-Containing 3 Protein; Obesity; Random Allocation | 2019 |
Carbenoxolone enhances peripheral insulin sensitivity and GLUT4 expression in skeletal muscle of obese rats: Potential participation of UBC9 protein.
Topics: Animals; Anti-Ulcer Agents; Carbenoxolone; Gene Expression Regulation; Glucose Transporter Type 4; Hyperinsulinism; Insulin Resistance; Male; Muscle, Skeletal; Obesity; Rats; Rats, Wistar; Ubiquitin-Conjugating Enzymes | 2019 |
Carbenoxolone ameliorates hepatic lipid metabolism and inflammation in obese mice induced by high fat diet via regulating the JAK2/STAT3 signaling pathway.
Topics: Animals; Anti-Inflammatory Agents; Anti-Obesity Agents; Carbenoxolone; Diet, High-Fat; Hypolipidemic Agents; Janus Kinase 2; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Obesity; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein | 2019 |
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Administration, Oral; Animals; Azepines; Carbenoxolone; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Obesity; Pioglitazone; Thiazolidinediones; Triazoles | 2014 |
Reduction of hepatic glucocorticoid receptor and hexose-6-phosphate dehydrogenase expression ameliorates diet-induced obesity and insulin resistance in mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Blood Glucose; Body Weight; Carbenoxolone; Carbohydrate Dehydrogenases; Cells, Cultured; Corticosterone; Deoxyglucose; Dietary Fats; Gene Expression; Glucose Tolerance Test; Hepatocytes; Homeostasis; Immunoblotting; Insulin; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; Receptors, Glucocorticoid; RNA, Messenger | 2008 |
Blockade of glucocorticoid excess at the tissue level: inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 as a therapy for type 2 diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Animals; Carbenoxolone; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucocorticoids; Glycyrrhetinic Acid; Humans; Insulin Resistance; Obesity | 2008 |
Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adiposity; Animals; Anti-Obesity Agents; Brain; Carbenoxolone; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Energy Metabolism; Enzyme Inhibitors; Female; Glucose-6-Phosphatase; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Mice; Mice, Mutant Strains; Obesity; Pancreas; Phosphoenolpyruvate Carboxykinase (ATP) | 2012 |
Carbenoxolone treatment ameliorated metabolic syndrome in WNIN/Ob obese rats, but induced severe fat loss and glucose intolerance in lean rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipocytes; Adipose Tissue; Adrenal Glands; Animals; Body Composition; Carbenoxolone; Cholesterol, HDL; Corticosterone; Eating; Enzyme Inhibitors; Fibrosis; Gene Expression Regulation; Glucose Intolerance; Glycogen; Hypertrophy; Liver; Male; Metabolic Syndrome; Obesity; Organ Size; Rats; Signal Transduction; Thinness; Triglycerides | 2012 |
Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Carbenoxolone; Eating; Glucose Tolerance Test; Hydroxysteroid Dehydrogenases; Hypothalamo-Hypophyseal System; Lipids; Obesity; Oxidoreductases; Pituitary-Adrenal System; Rats; Rats, Zucker; Weight Gain | 2003 |
Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 11-beta-Hydroxysteroid Dehydrogenase Type 2; Carbenoxolone; Cortisone; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hydrocortisone; Insulin Resistance; Liver X Receptors; Middle Aged; Muscle Fibers, Skeletal; Obesity; Orphan Nuclear Receptors; Receptors, Cytoplasmic and Nuclear; Receptors, Glucocorticoid | 2005 |
Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Agouti Signaling Protein; Animals; Atherosclerosis; Blood Pressure; Body Weight; Carbenoxolone; Corticosterone; Energy Metabolism; Fatty Liver; Female; Hyperinsulinism; Hyperlipidemias; Lipoproteins, VLDL; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Obese; Obesity; Receptors, LDL | 2007 |
Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Blood Glucose; Body Weight; Carbenoxolone; Corticosterone; Dietary Fats; Eating; Glucose Tolerance Test; Insulin; Insulin Resistance; Male; Mice; Obesity; Receptors, Glucocorticoid; Reverse Transcriptase Polymerase Chain Reaction | 2008 |